Your browser doesn't support javascript.
loading
Increased cancer incidence and mortality among people with opioid use-related disorders: A nation-wide cohort study.
Kostovski, Emil; Hamina, Aleksi; Hjellvik, Vidar; Clausen, Thomas; Skurtveit, Svetlana.
Afiliação
  • Kostovski E; Manifestsenteret, Røyken, Norway.
  • Hamina A; Niuvanniemi Hospital, Kuopio, Finland.
  • Hjellvik V; Norwegian Centre for Addiction Research (SERAF), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Clausen T; Department of Chronic Diseases, Division of Mental and Physical Health, The Norwegian Institute of Public Health, Oslo, Norway.
  • Skurtveit S; Norwegian Centre for Addiction Research (SERAF), Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Addiction ; 119(9): 1575-1584, 2024 Sep.
Article em En | MEDLINE | ID: mdl-38775233
ABSTRACT
BACKGROUND AND

AIMS:

Studies on cancer incidence and mortality among people with opioid use-related disorders are lacking. We aimed to measure cancer-specific incidence, mortality and survival among people diagnosed with opioid use-related disorders in Norway during 2010-18. DESIGN AND

SETTING:

This was a cohort study conducted in Norway during 2010-18.

PARTICIPANTS:

Individuals (n = 20 710) diagnosed with opioid use-related disorders. MEASUREMENTS We conducted a cohort study utilizing a data-linkage of national health and population registers. Information on opioid use-related disorders was extracted from specialized healthcare, malignancies from the Cancer Registry of Norway and deaths from Cause of Death Registry. Cancer incidence and mortality were compared with the general population by calculating sex-specific age-standardized incidence (SIR) and mortality (SMR) ratios. One-year survival rates were computed.

FINDINGS:

Compared with the general population, people with opioid use-related disorders were at an increased risk of developing cancer overall [SIR = 1.2, 95% confidence interval (CI) = 1.1-1.3] with a higher than twofold cancer mortality rate (SMR = 2.3, 95% CI = 2.0-2.7). Excess risk was observed for liver (12.6, 95% CI = 9.1-17.0), larynx (4.7, 95% CI = 1.7-10.2), lung (3.5, 95% CI = 2.8-4.3) and pancreas cancer (2.6, 95% CI = 1.6-4.0), whereas reduced risk was found for melanoma (0.5, 95% CI = 0.3-0.9), breast (0.6, 95% CI = 0.4-0.9) and prostate cancers (0.3, 95% CI = 0.1-0.4). Site-specific SMRs were significantly elevated for liver (12.3, 95% CI = 8.5-17.2), lung (3.9, 95% CI = 3.0-5.0), pancreas (3.0, 95% CI = 1.7-4.8) and colon cancers (1.9, 95% CI = 1.1-3.1). The average 1-year survival rate after a cancer diagnosis was low in liver, pancreas and colon cancer, ranging from 10 to 15% less than that of the general population.

CONCLUSIONS:

In Norway, cancer incidence and cancer-related mortality appear to be elevated among individuals with opioid use-related disorders.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistema de Registros / Transtornos Relacionados ao Uso de Opioides / Neoplasias Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistema de Registros / Transtornos Relacionados ao Uso de Opioides / Neoplasias Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article